Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPR1020 in Advanced Solid Tumors
NCT07359066Phase 2Recruiting
- Sponsor
- SciBrunch Therapeutics
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SPR1020 in solid tumor, sponsored by SciBrunch Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
SPR1020
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07359066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359066.